BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20496792)

  • 1. [Efficacy and safety of pancrealipase delayed-release capsules (Creon) in patients with pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery].
    Vitkomb D; Maleska-Panas E; Lekhman G; Vasil'eva N; Gubergrits N; Karas S; Shen Ia; Sander-Strukmaer S
    Eksp Klin Gastroenterol; 2010; (3):65-70. PubMed ID: 20496792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
    Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
    Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
    Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
    Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
    J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
    Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
    Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience with the use of 13C-breath test for the evaluation of the efficacy of enzyme substitution therapy with microencapsulated pancreatinin in patients with severe primary pancreatic insufficiency].
    Rapoport SI; Maev IV; Kucheriavyĭ IuA; Shubina NA; Semenova NV; Stukova NIu; Archakov AI
    Klin Med (Mosk); 2009; 87(1):53-7. PubMed ID: 19256262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
    J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
    Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency.
    Sander-Struckmeier S; Beckmann K; Janssen-van Solingen G; Pollack P
    Pancreas; 2013 Aug; 42(6):983-9. PubMed ID: 23587850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
    Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
    Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
    Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
    Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancrelipase for pancreatic disorders: An update.
    Dhanasekaran R; Toskes PP
    Drugs Today (Barc); 2010 Nov; 46(11):855-66. PubMed ID: 21225024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral pancreatic enzyme substitution therapy in chronic pancreatitis: is clinical response an appropriate marker for evaluation of therapeutic efficacy?
    Domínguez-Muñoz JE; Iglesias-García J
    JOP; 2010 Mar; 11(2):158-62. PubMed ID: 20208327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic enzyme pharmacotherapy.
    Ferrone M; Raimondo M; Scolapio JS
    Pharmacotherapy; 2007 Jun; 27(6):910-20. PubMed ID: 17542772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.
    Knop FK; Vilsbøll T; Lund A; Krarup T; Holst JJ; Hornum M
    JOP; 2010 Sep; 11(5):489-91. PubMed ID: 20818126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.